Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 783 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Endometrium Cancer Clear all
Withdrawn No phase listed Observational

Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC)

NCT00250016
View directory record Official record
Conditions
Corpus Uteri, Endometrial Cancer
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 5, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

NCT00044876
View directory record Official record
Conditions
Leiomyoma
Interventions
CDB-2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
33 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 5, 2026, 5:45 PM EDT
Completed Not applicable Interventional

GYNecologic Cancer-Related COGnitive Impairment

NCT06662435
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Cervical Cancers, Vulvar Cancers, Uterine Cancer, Cervix Cancer, Ovary Cancer
Interventions
GYNCOG
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 5, 2026, 5:45 PM EDT
Recruiting Not applicable Interventional

Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy

NCT07662824
View directory record Official record
Conditions
Cervical Carcinoma, Endometrial Carcinoma, Overactive Bladder, Voiding Disorders
Interventions
Educational Intervention, Interview, Flyte Medical Device Usage and Evaluation, Questionnaire Administration, Referral
Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 5, 2026, 5:45 PM EDT
Active, not recruiting No phase listed Observational

Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy

NCT04713618
View directory record Official record
Conditions
Anal Carcinoma, Cervical Carcinoma, Endometrial Carcinoma, Malignant Pelvic Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Pelvic Examination, Survey
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 5, 2026, 5:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Michigan Genetic Hereditary Testing (MiGHT)

NCT05162846
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
Interventions
Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI)
Other · Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 5, 2026, 5:45 PM EDT
Completed Not applicable Interventional Results available

Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer

NCT01045187
View directory record Official record
Conditions
Endometrial Cancer
Interventions
brachytherapy, Xoft Axxent Electronic Brachytherapy System
Radiation
Lead sponsor
Xoft, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Casa Grande, Arizona • Phoenix, Arizona • Montebello, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 5, 2026, 5:45 PM EDT
Terminated Phase 3 Interventional Results available

Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer

NCT00577317
View directory record Official record
Conditions
Lymphedema, Stage 0 Cervical Cancer, Stage 0 Uterine Corpus Cancer, Stage 0 Vulvar Cancer, Stage I Uterine Corpus Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Uterine Corpus Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vulvar Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage IVB Vulvar Cancer
Interventions
Management of Therapy Complications, Quality-of-Life Assessment
Procedure · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 5, 2026, 5:45 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer

NCT05877404
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Surveys
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 5, 2026, 5:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women

NCT00099008
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer
Interventions
Genistein, Placebo
Dietary Supplement
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 5, 2026, 5:45 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

NCT04681248
View directory record Official record
Conditions
Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, GastroEsophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma, Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma, Gastric Cancer
Interventions
DKN-01
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 5, 2026, 5:45 PM EDT
Recruiting Not applicable Interventional

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)

NCT05743517
View directory record Official record
Conditions
Ovary Cancer, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Cervix Cancer, Vulvar Cancer, Vaginal Cancer
Interventions
Fit4Treatment
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
60 Years and older · Female only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 5, 2026, 5:45 PM EDT
Not listed No phase listed Observational

Tumor Grade Determines PD-1/PDL-1 Expression

NCT04528940
View directory record Official record
Conditions
Endometrial Cancer, Ovarian Cancer
Interventions
PD-1/PDL-1 staining
Diagnostic Test
Lead sponsor
RWJ Barnabas Health at Jersey City Medical Center
Other
Eligibility
Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Sep 5, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

RAD001 in Recurrent Endometrial Cancer Patients

NCT00087685
View directory record Official record
Conditions
Endometrial Cancer
Interventions
RAD001
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 5, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972
View directory record Official record
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 5, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

NCT00003691
View directory record Official record
Conditions
Endometrial Cancer
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Sep 5, 2026, 5:45 PM EDT
Recruiting No phase listed Observational

Endometrial Cancer Vaginal Fluid Specimen Collection Study

NCT07544680
View directory record Official record
Conditions
Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia, Endometrial Intraepithelial Neoplasia
Interventions
Not listed
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Sarasota, Florida • Scarborough, Maine • Murfreesboro, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 5, 2026, 5:45 PM EDT
Active, not recruiting Not applicable Interventional

Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers

NCT02774759
View directory record Official record
Conditions
Malignant Neoplasms of Female Genital Organs
Interventions
Accelerometer, Questionnaires, Fitness Test, Resistance Training, Aerobic Exercise, Telephone Coaching/Phone Calls, Video Chat Sessions
Device · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 5, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer

NCT00003669
View directory record Official record
Conditions
Endometrial Cancer
Interventions
arzoxifene hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
10
States / cities
Pasadena, California • Columbia, Missouri • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Sep 5, 2026, 5:45 PM EDT
Active, not recruiting No phase listed Observational

Weight Loss Management in Endometrial Cancer Survivors

NCT06877572
View directory record Official record
Conditions
Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer
Interventions
Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 5, 2026, 5:45 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

NCT05856981
View directory record Official record
Conditions
Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer, RCC, Clear Cell Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Endometrial Cancer
Interventions
ADU-1805, Pembrolizumab
Drug
Lead sponsor
Sairopa B.V.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Detroit, Michigan • St Louis, Missouri • Canton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 5, 2026, 5:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging

NCT04514692
View directory record Official record
Conditions
Cervix Cancer, Endometrial Cancer
Interventions
GCSF
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 5, 2026, 5:45 PM EDT
Not listed Phase 2Phase 3 Interventional Results available

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

NCT02065687
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride, Paclitaxel, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
431
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 298 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Sep 5, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus

NCT02744898
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Carboplatin AUC, Abraxane
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 5, 2026, 5:45 PM EDT